WealthTrust Axiom LLC Buys 20,112 Shares of Pfizer Inc. (NYSE:PFE)

WealthTrust Axiom LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 19.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 121,607 shares of the biopharmaceutical company’s stock after acquiring an additional 20,112 shares during the period. Pfizer comprises 1.2% of WealthTrust Axiom LLC’s investment portfolio, making the stock its 19th biggest position. WealthTrust Axiom LLC’s holdings in Pfizer were worth $3,501,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Trifecta Capital Advisors LLC lifted its stake in shares of Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 325 shares during the period. Confluence Wealth Services Inc. lifted its position in Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares during the period. Carr Financial Group Corp grew its position in shares of Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares during the period. Caldwell Sutter Capital Inc. raised its stake in shares of Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after buying an additional 364 shares during the last quarter. Finally, Bill Few Associates Inc. lifted its holdings in Pfizer by 0.5% in the third quarter. Bill Few Associates Inc. now owns 80,820 shares of the biopharmaceutical company’s stock valued at $2,681,000 after buying an additional 368 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.0 %

Shares of Pfizer stock traded up $0.01 on Tuesday, hitting $25.65. The company had a trading volume of 25,345,365 shares, compared to its average volume of 41,798,219. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a 50-day moving average of $26.92 and a 200-day moving average of $28.31. The firm has a market capitalization of $145.24 billion, a P/E ratio of 71.50, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 EPS. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.